Primary packaging decisions for sensitive biologic injectables go beyond the technical performance of an individual component. Consistency, product compatibility and continuity of supply can affect the drug product, manufacturing operations and ultimately the patient. In this live 360° dialogue, experts from UCB and Aptar Pharma will bring drug manufacturer and primary packaging perspectives to the same table. They will explore how upstream quality, contamination control, platform strategies, multisourcing and packaging flexibility can strengthen performance and supply resilience across different products and manufacturing environments. Participants will gain a practical framework for evaluating primary packaging solutions and partners, identifying potential gaps and aligning quality, technical and supply requirements earlier in the product lifecycle.
After attending this webinar, participants will be able to:
-
- Recognise the heightened primary packaging considerations associated with sensitive biologic injectables, and how these can inform packaging decisions across injectable therapies.
-
- Evaluate primary packaging solutions and partners through a 360° framework connecting component performance, upstream quality, platform fit, flexibility and supply resilience.
-
- Apply practical questions drawn from pharmaceutical and primary packaging perspectives to identify quality, technical and supply risks earlier during selection and qualification.
